ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Show other versions (1)

<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span lang="EN-US">Allogeneic conventional hemato...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed L. Sorror, Rainer F. Storb
Format: Article
Language:English
Published: PAGEPress Publications 2010-05-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Myelodysplasia , Hemopoietic Stem Cell Transplantation, Risk Factors
Online Access:http://www.mjhid.org/article/view/6042
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846143892468006912
author Mohamed L. Sorror
Rainer F. Storb
author_facet Mohamed L. Sorror
Rainer F. Storb
author_sort Mohamed L. Sorror
collection DOAJ
description <p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span lang="EN-US">Allogeneic conventional hematopoietic cell transplantation (HCT) following high-dose, myeloablative conditioning regimens has been used since the 1970’s as potentially curative treatment for </span><span style="line-height: 200%; mso-bidi-font-size: 11.0pt; mso-bidi-font-family: Arial;" lang="EN-US">patients with malignant, hematological disorders</span><span lang="EN-US">. </span><span style="line-height: 200%; mso-bidi-font-size: 11.0pt; mso-bidi-font-family: Arial;" lang="EN-US">The toxicities of conditioning regimens have limited conventional HCT to relatively young patients in otherwise good medical condition.</span><span lang="EN-US"> </span><span style="line-height: 200%; mso-bidi-font-size: 11.0pt; mso-bidi-font-family: Arial;" lang="EN-US">With the development of less toxic nonmyeloablative regimens and improvements in supportive care, increasing numbers of older and medically infirm patients have been treated by allogeneic HCT. </span><span lang="EN-US">Until recently, there has been almost no effort to evaluate the prevalence of comorbidities among HCT recipients and their impact on outcomes. We first evaluated the Charlson Comorbidity Index (CCI) developed for patients with solid malignancies, for this purpose. While useful, it lacked sensitivity and specificity for the HCT setting. We next introduced the HCT-specific comorbidity index (HCT-CI) which was based on objective laboratory data to better define comorbidities. Here, we describe this development and illustrate the usefulness of the HCT-CI in predicting HCT outcomes in patients with myeloid and lymphoid malignancies undergoing allogeneic transplantation</span></span></span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%;"><span lang="EN-US"><span style="font-size: small; font-family: Times New Roman;"> </span></span></p>
format Article
id doaj-art-bb41c1ef0f5442f4a3bc1737ea8ff9b5
institution Kabale University
issn 2035-3006
language English
publishDate 2010-05-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-bb41c1ef0f5442f4a3bc1737ea8ff9b52024-12-02T09:48:52ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062010-05-0122e2010015e2010015ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATIONMohamed L. SorrorRainer F. Storb<p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%;"><span style="font-size: small;"><span style="font-family: Times New Roman;"><span lang="EN-US">Allogeneic conventional hematopoietic cell transplantation (HCT) following high-dose, myeloablative conditioning regimens has been used since the 1970’s as potentially curative treatment for </span><span style="line-height: 200%; mso-bidi-font-size: 11.0pt; mso-bidi-font-family: Arial;" lang="EN-US">patients with malignant, hematological disorders</span><span lang="EN-US">. </span><span style="line-height: 200%; mso-bidi-font-size: 11.0pt; mso-bidi-font-family: Arial;" lang="EN-US">The toxicities of conditioning regimens have limited conventional HCT to relatively young patients in otherwise good medical condition.</span><span lang="EN-US"> </span><span style="line-height: 200%; mso-bidi-font-size: 11.0pt; mso-bidi-font-family: Arial;" lang="EN-US">With the development of less toxic nonmyeloablative regimens and improvements in supportive care, increasing numbers of older and medically infirm patients have been treated by allogeneic HCT. </span><span lang="EN-US">Until recently, there has been almost no effort to evaluate the prevalence of comorbidities among HCT recipients and their impact on outcomes. We first evaluated the Charlson Comorbidity Index (CCI) developed for patients with solid malignancies, for this purpose. While useful, it lacked sensitivity and specificity for the HCT setting. We next introduced the HCT-specific comorbidity index (HCT-CI) which was based on objective laboratory data to better define comorbidities. Here, we describe this development and illustrate the usefulness of the HCT-CI in predicting HCT outcomes in patients with myeloid and lymphoid malignancies undergoing allogeneic transplantation</span></span></span></p><p class="MsoNormal" style="margin: 0cm 0cm 0pt; line-height: 200%;"><span lang="EN-US"><span style="font-size: small; font-family: Times New Roman;"> </span></span></p>http://www.mjhid.org/article/view/6042Myelodysplasia , Hemopoietic Stem Cell Transplantation, Risk Factors
spellingShingle Mohamed L. Sorror
Rainer F. Storb
ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Mediterranean Journal of Hematology and Infectious Diseases
Myelodysplasia , Hemopoietic Stem Cell Transplantation, Risk Factors
title ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_full ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_fullStr ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_full_unstemmed ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_short ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
title_sort role of comorbidities in optimizing decision making for allogeneic hematopoietic cell transplantation
topic Myelodysplasia , Hemopoietic Stem Cell Transplantation, Risk Factors
url http://www.mjhid.org/article/view/6042
work_keys_str_mv AT mohamedlsorror roleofcomorbiditiesinoptimizingdecisionmakingforallogeneichematopoieticcelltransplantation
AT rainerfstorb roleofcomorbiditiesinoptimizingdecisionmakingforallogeneichematopoieticcelltransplantation

Similar Items